Hyperion Therapeutics to broaden orphan disease pipeline with buy of Israeli firm
US biotech firm Hyperion Therapeutics (Nasdaq: HPTX) has entered into a definitive agreement to acquire Andromeda Biotech, an Israel-based subsidiary of Clal Biotechnology Industries (CBI: TA), in a deal that could be worth nearly $600 million.
At the closing of the transaction, Hyperion will pay $12.5 million in cash, less adjustments for expenses, and 312,869 shares of Hyperion common stock (valued at about $7.85 million based on the average closing price of $25.09 per share for the 15 consecutive trading days ending April 17, 2014). Hyperion will potentially make contingent payments to Andromeda security holders, as follows:
- potential global regulatory and approval milestones payments that total $120 million, the first of which would not be made until acceptance of the first marketing application filing for review in either the USA or Europe, whichever occurs first;
- up to $430 million in commercial milestones, the first of which would be due upon achievement of annual worldwide net sales of $450 million; and
- tiered contingent sales payments ranging from 10% on annual worldwide net sales up to $300 million to 17% sales that exceed $1.2 billion, with the exception of sales by distributors in certain territories, for which the rate is 25%.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Biotechnology
| Headless Content Management with Blaze